Menu Close
scroll
Urology

SONABLATE HIFU

High-Intensity Focussed Ultrasound (HIFU)
for targeted Therapy of Prostate Carcinoma

Overview

Earlier, precise diagnostic of prostate cancer demands a paradigm change respectively a new treatment pathway.

Advantages

  • Licensed MRI/US fusion from original fusion biopsy providers for high precision of the treatment
  • Adjustable for each single dose of HIFU energy
  • Enable to response individually to the patient’s prostate tissue reaction
  • Non-invasive, bloodless ablation
  • Healthy tissue sparing
  • Low side effects Repeatable procedure, if indicated
  • Radiation-free
  • Cost efficient


Learn more on:
sonacaremedical.com

The Probe

The Sonablate probe delivers precise and focused ablative energy into the prostate. Various planning and control functions allow an individually adapted treatment of the prostate.

The Sonasource

The Sonasource console powers the Sonablate probe. It is comprised of several integrated programmable hardware and software modules that are used to drive and control SonaCare Medical's probes.

Also included with Sonasource is Sonachill, a water degasser, cooler and circulator used to ensure temperature stabilization and acoustic coupling.

Sonablate Disposable Kit

It is comprised of a sterile probe tip pack and a water path kit. The probe tip allows sterile patient contact required for acoustic coupling between the target tissue and energy source.

SonaFuse

The HIFU fusion platform follows an open architecture approach for the validated integration of existing mpMRI fusion biopsy platforms into the Sonablate planning software.

Segmented and annotated MRI images are imported into Sonablate and merged with live ultrasound images.

Sonablate Safety Features

Features such as Tissue Change Monitoring (TCM), Total Acoustic Power (TAP), Reflexivity Index Monitor (RIM) and others enable the surgeon to respond individually to the patient's prostate and form the basis for successful, sustainable results with fewer side effects.

SELECTED PUBLICATIONS
September 2019
Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer
Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C, Freeman A, McCartan N, Montorsi F, Briganti A, Ahmed HU, Emberton M, Moore CM: Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019 Sep;124(3):431-440. doi: 10.1111/bju.14710. Epub 2019 Mar 18.
June 2018
A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
S. Guillaumier, M. Peters, M. Arya, N. Afzal, S. Charman, T. Dudderidge, F. Hosking-Jervis, R. G. Hindley, H. Lewi, N. McCartan, C. M. Moore, R. Nigam, C. Ogden, R. Persad, K. Shah, J. van der Meulen, J. Virdi, M. Winkler, M. Emberton, H. U. Ahmed: A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol. 2018 Oct;74(4):422-429. doi: 10.1016/j.eururo.2018.06.006. Epub 2018 Jun 28.
April 2017
Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer
A. Kanthabalan, M. Peters, M. Van Vulpen, N. McCartan, R. G. Hindley, A. Emara, C. M. Moore, M. Arya, M. Emberton and H. U. Ahmed: Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. BJU Int. 2017 Aug;120(2): 246-256. doi: 10.1111/bju.13831. Epub 2017 Apr 3.
January 2015
Improved Outcomes with Advancements in High Intensity Focused Ultrasound Devices for the Treatment of Localized Prostate Cancer
Toyoaki Uchida, Tetsuro Tomonaga, Hakushi Kim, Mayura Nakano, Sunao Shoji, Yoshihiro Nagata and Toshiro Terachi: Improved Outcomes with Advancements in High Intensity Focused Ultrasound Devices for the Treatment of Localized Prostate Cancer. J Urol. 2015 Jan;193(1):103-10. doi: 10.1016/j.juro.2014.07.096. Epub 2014 Jul 28.